Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study With Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects With Advanced Solid Tumors

NCT05821777 is registered in ClinicalTrials.gov with Centessa Pharmaceuticals (UK) Limited as lead sponsor.

NCT NCT05821777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study With Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects With Advanced Solid Tumors
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
March 28, 2023
Completion date
September 9, 2025
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor